详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

单位： [1]Endocrine Department, China-Japan Friendship Hospital, Beijing, China [2]Endocrine Department, Nanjing First Hospital, Nanjing Medical University, Nanjing, China [3]Endocrine Department, Affiliated Hospital of Jiangsu University, Zhenjiang, China [4]Endocrine Department, Shengjing Hospital of China Medical University, Shenyang, China [5]Endocrine Department, Qingpu Branch of Zhongshan Hospital, Affiliated with Fudan University, Shanghai, China [6]EndocrineDepartment, The SecondAffiliated Hospital, NanjingMedical University, Nanjing, China [7]Endocrine Department, Changzhou Second People's Hospital, Affiliated with Nanjing Medical University, Changzhou, China [8]Endocrine Department, Chenzhou No. 1 People's Hospital, Chenzhou, China [9]Endocrine Department, Tianjin Medical University General Hospital, Tianjin, China [10]Endocrine Department, The Third Hospital of Wuhan, Wuhan, China [11]Endocrine Department, Lishui People's Hospital, Lishui, China [12]Medical Department, Sanofi Investment Co., Ltd., Shanghai, China [13]Endocrine Department, Beijing Tongren Hospital, Beijing, China

出处：

DOI：

ISSN：

关键词： fasting blood glucose glycated haemoglobin insulin glargine type 2 diabetes

摘要：

The optimal fasting blood glucose (FBG) target of achieving HbA1c less than 7.0% in type 2 diabetes (T2D) patients remains controversial. This open-label trial randomized (1:3:3) 947 adults with uncontrolled T2D (HbA1c >7% to <= 10.5%) who were using one to three oral antidiabetic drugs to achieve an FBG target of 3.9 < FBG <= 5.6 mmol/L (Group 1), 3.9 < FBG <= 6.1 mmol/L (Group 2) or of 3.9 < FBG <= 7.0 mmol/L (Group 3). Targets were achieved using a pre-defined insulin glargine 100 U/mL titration scheme. The primary endpoint was proportion of patients achieving HbA1c <7.0% at 24 weeks. At 24 weeks, 44.4%, 46.1% and 37.7% of patients achieved HbA1c <7.0% in Groups 1, 2 and 3, respectively (P = 0.017; Group 2 vs Group 3). Alert hypoglycaemia (glucose <= 3.9 mmol/L) was significantly more frequent in Group 1 than in Group 3 (38.9 vs 23.3%; P < 0.001) but was not in Group 2 vs Group 3 (27.5% vs 23.3%; P = 0.177). Clinically important hypoglycaemia (glucose <= 3.0 mmol/L) was reported in 4.8%, 2.0% and 3.8% of patients in Groups 1, 2 and 3, respectively. In conclusion, the optimal FBG target for most Chinese patients with T2D appears to be 3.9-6.1 mmol/L.

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 1 区

医学

小类 | 1 区内分泌学与代谢

最新[2025]版：

大类 | 2 区医学

小类 | 2 区内分泌学与代谢

JCR分区：

出版当年[2017]版：

Q1 ENDOCRINOLOGY & METABOLISM

最新[2023]版：

Q1 ENDOCRINOLOGY & METABOLISM

影响因子： 最新[2023版] 5.4 最新五年平均[2021-2025] 5.5 出版当年[2017版] 5.98 出版当年五年平均[2013-2017] 5.888 出版前一年[2016版] 6.715 出版后一年[2018版] 6.133

第一作者：

第一作者单位： [1]Endocrine Department, China-Japan Friendship Hospital, Beijing, China [*1]Endocrine Department, China-Japan Friendship Hospital, East Yinghuayuan Street, Hepingli, Beijing 100029, People's Republic of China

通讯作者：

通讯机构： [1]Endocrine Department, China-Japan Friendship Hospital, Beijing, China [*1]Endocrine Department, China-Japan Friendship Hospital, East Yinghuayuan Street, Hepingli, Beijing 100029, People's Republic of China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial

文献详情

相关文献